Lege Artis Medicinae

[THE WORLDWIDE EPIDEMIC OF TYPE 2 DIABETES - CAUSES AND CONSEQUENCES]

JERMENDY György

FEBRUARY 21, 2006

Lege Artis Medicinae - 2006;16(02)

[The prevalence of type 2 diabetes mellitus has recently dramatically increased worldwide. While many factors contribute to the startling data, including changes in the diagnostic criteria of glucose intolerance, increase of life expectancy, manifestation of diabetes at younger ages, and increased detection of unrecognized diabetes due to more efficient screening, the genuine, steep rise in the incidence of diabetes is explained by the increasing prevalence of obesity. Among the late complications of both diabetes and obesity, cardiovascular diseases are particularly important. Insulin resistance due to visceral obesity plays a central role in the pathomechanism of type 2 diabetes. In the prevention of both type 2 diabetes and obesity, non-pharmacological intervention such as life style changes should be considered first. Supplementary pharmacological treatment should target all cardiovascular risk factors.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Restorative impact of rabeprasole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance]

NEMESÁNSZKY Elemér

Lege Artis Medicinae

[Navigare Necesse Est A Discussion with Béla Buda MD]

FERENCZI Andrea

Lege Artis Medicinae

[THE PROBLEM OF CHILDHOOD OBESITY]

RODÉ Magdolna

[Obesity represents a major public health problem in both developed and developing countries having rapidly increased in prevalence in the past two decades. Childhood obesity is of particular concern. Two of its associated diseases require special attention; metabolic syndrome and type 2 diabetes one of its components that are increasingly diagnosed in childhood. A key to prevention and treatment is healthy lifestyle. The importance of education to healthy lifestyle from early childhood cannot be overemphasized.]

Lege Artis Medicinae

[OVARIAN CHORIOCARCINOMA - A MOLECULAR PATHOLOGIC APPROACH TO DIFFERENTIAL DIAGNOSIS]

ERÉNYI Éva, SZIGETVÁRI Iván, ANDRIKOVICS Hajnalka, TORDAI Attila, URBÁN Márta, SIMON Károly

[INTRODUCTION - Gestational and non-gestational choriocarcinoma, the two types of choriocarcinoma with distinct aetiologies, cannot be differentiated by conventional histological or immunohistochemical methods. In certain cases the verification of the origin of the tumour by molecular biological techniques is essential for prognostic and therapeutic reasons. CASE REPORT - A 22-year-old woman presenting with acute abdominal pain was examined and operated on. During surgery a tumour was found in the right ovary. “Pure” choriocarcinoma was histologically diagnosed and gestational origin was supposed based on the distinct clinical features and histological picture. This was subsequently confirmed by molecular genetic testing. Parallel VNTR (variable number of tandem repeats) analysis by PCR of DNA from the tumour tissue and the patient's peripheral blood was performed. The pattern showed the presence of an allele presumed to be of paternal origin. (Blood sample from the father was not available.) One regimen of Vepesid, Cisplatina and Bleomycin was applied, and more than three years after the diagnosis the patient is free of disease. CONCLUSION - Multidisciplinary cooperation led to an accurate diagnosis and successful treatment. Non-radical surgery with the preservation of fertility followed by proper early chemotherapy provided excellent results.]

Lege Artis Medicinae

[SCIENTIFIC DIGEST]

All articles in the issue

Related contents

Lege Artis Medicinae

[METABOLIC “X” SYNDROME: “XYNDROME” - POSITIONS AND OPPOSITIONS]

MATOS Lajos

[The idea of a constellation of abnormalities linked to insulin resistance as a key component was pioneered and summarized by Reaven in 1988 under the name of “X” syndrome. Based on the various elements of the syndrome, several synonyms have been proposed, including “deadly trio”, “deadly quartet”, “central fat syndrome”, “insulin resistance syndrome”. To avoid the confusion of this entity with “cardial X syndrome”, an established syndrome in cardiology, and instead of the rather long “metabolic X syndrome”, I have proposed the term “Xyndrome”. Irrespective of how it is called, this syndrome has come into the focus of clinical research; using the keyword “metabolic syndrome” to search in the index of the National Library of Medicine, 15.661 citations pop up, and in February 2006 only, 168 papers were published in this field. In spite of this, several international scientific organizations have recently claimed that metabolic syndrome has not been unambiguously defined, its diagnostic criteria are contradictory, and finally, the syndrome as an entity has no more value in predicting cardiovascular risk than the sum of its individual components has, therefore, the use of this notion in the clinical practice is not recommended. There are, however, opposing opinions emphasizing the importance of abdominal obesity - today considered to be most essential element -, data from recent research, and the didactic advantage that the use of this notion has improved complex treatment of its various components. It is crucial to understand that “syndrome” is not more - and not less, either - than a clustering of symptoms and findings, and should not be treated as a distinct disease. The emergence of the notion of metabolic syndrome, however, has been a step forward in the medical concept in that metabolic and cardiovascular diseases are now dealt with in a more complex way, which warrants the maintenance of this notion and the increase of our understanding by continuing research in this field.]

Lege Artis Medicinae

[Antidiabetic therapy of patients with type 2 diabetes - The role of incretin mimetics]

GERŐ László

[Incretin mimetics represent a new group of antidiabetic drugs. They bind to their own receptor on the beta-cell membrane and increase insulin secretion in a glucosedependent manner. Thus, they rarely cause hypoglycaemia. Furthermore, they significantly reduce body weight and other cardiovascular risk factors. Accordingly, they can be considered as an optimal group of antidiabetic drugs. The author reviews the clinical efficacy and safety of currently available incretin mimetics.]

Journal of Nursing Theory and Practice

[Contact between the polycystic ovary syndrome and the metabolic syndrome]

KISS Katalin, VÁRADYNÉ HORVÁTH Ágnes, PAKAI Annamária

[Aim of the study: The objective of my thesis was to examine the presence of metabolic syndrome with the disorder of glucose metabolism among patients diagnosed with polycystic ovary syndrome (PCOS). Sample and methods: 98 female patients diagnosed with PCOS, aged 18-45, took part in the retrospective quantitative study, anthropometric data and laboratory parameters relevant to metabolic profile were analysed. We applied descriptive statistics with SPSS 17 software, as well as Chi2-test and regression analysis (p <0.05) Results: 46% of the study population were found to be overweight. There was a significant correlation between BMI index and blood pressure and lipid profile (p<0.05). Metabolic syndrome was confirmed by more than 40% of the patients Conclusion: The PCOS is an endocrine disease, which affects multiple organ systems. The patients should be screened towards metabolic syndrome to achieve a correct diagnosis, regardless of the BMI values. The findings of our research and the confirmed correlations highlight the need for a development in care protocols.]

Hypertension and nephrology

[Hyperuricemia and cardiovascular risk: new treat to target principle in focus]

ALFÖLDI Sándor

[Hyperuricemia is frequent and its prevalence is increasing as it correlates with obesity and metabolic syndrome by several different mechanisms. Furthermore, recently several data are available for the cardiovascular and renal protective effect of allopurinol in the treatment of hyperuricemia and gout. The new European EULAR guidelines suggested treat to target principle in urat lowering therapy of gout. The uric acid target is below 360 µmol/l in mild to moderate gout. The guidelines unequivocally stated, that allopurinol is the first line uric acid lowering drug. Allopurinol treatment should be started immediately at the diagnosis and should be continued lifelong.]

Image challenge

What do you see on the feet of the diabetic patient?